Drug Trial Radar · NCT04379271
A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)
Last checked: Nov 19, 2026Latest source record: Nov 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
234
Actual
Start
Jun 11, 2020
Primary completion
Jan 12, 2021
Study completion Feb 23, 2021
Sponsor
- Lead sponsor
- Immunic AGIndustry
- Sponsor type
- Industry
- Collaborators
- FGK Clinical Research GmbH
- First posted
- May 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
At present there is no approved drug treatment for Covid-19. In this study we plan to investigate if an experimental drug called IMU-838 (vidofludimus calcium) can improve your symptoms, prevent worsening that would initiate further treatments such as ventilation, and can lower your virus number if given in addition to your doctor's choice of standard therapy. We will also test if IMU-838 has any side effects and measure the level of IMU 838 in your blood. Experimental drug means that it is not yet authorized for marketing in your country. To date approximately 600 individuals have received IMU-838 (or a drug similar to IMU-838 that contains the same active substance as IMU-838) in research studies.
Conditions
- COVID-19
Interventions
IMU-838Drug
Tablets will be taken BID with a glass of water (if possible); one tablet each in the morning (15 to 50 min before a meal if applicable), and in the evening (2 hours after any meal if applicable). If the patient is intubated for ventilation, IMP is to be given via a gastric tube. The tablet has no coating and a homogeneous content and can be crushed into smaller pieces (if necessary) for dosing via gastric tube.
PlaceboOther
Matching placebo, twice-daily administration BID as described for the test product, identical number of tablets as given for IMU-838
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Patients Without Any Need for INV Until EoSTime frame: Throughout the Study (Day 0 to Day 28)
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Military Medical Academy, Clinic of Infectious Diseases
Sofia, Bulgaria
UMHATEM N.I.Pirogov, Clinic of internal diseases
Sofia, Bulgaria
University Hospital Frankfurt, Infectious Diseases
Frankfurt, Germany
Clinic of the Hannover Medical School, Pneumology Clinic
Hanover, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.